CEO Mark Sawicki in Pharma Focus Asia on the Future of Cell & Gene Therapy 

 The cell and gene therapy (CGT) industry continues to introduce new breakthroughs shaping the future of medicine. In the latest issue of Pharma Focus Asia, Cryoport Systems’ CEO, Mark Sawicki, Ph.D., shares his expert insights on the key drivers of growth, the importance of standardization, and the critical role of a scalable supply chain in advancing the industry.   

 

A Vision for the Future of CGT 

In his exclusive interview, Mark explores the transformative changes expected in CGT by 2025 and beyond. The market is expanding rapidly, fueled by: 

  • Regulatory advancements – With seven FDA approvals in 2024 alone, the industry is on track for continued momentum. 
  • Technological innovations – AI, automation, and genome editing are revolutionizing manufacturing and therapeutic development. 
  • Standardized cryopreservation and comprehensive logistics – The ability to maintain product integrity across a global supply chain will be essential for scalability. 
The Challenge of Scaling Advanced Therapies 

One of the most pressing concerns in CGT today is scalability. Mark emphasizes that while demand is growing, companies must ensure that production keeps pace without compromising quality. Standardized cryopreservation, like Cryoport Systems’ IntegriCell™ services, is a key part of the solution, ensuring consistent cellular viability and enabling manufacturers to meet patient needs efficiently. 

 

Why This Matters 

As CGT therapies move toward commercialization, companies must navigate regulatory complexities, temperature-sensitive logistics, and global supply chain challenges. Mark’s insights highlight the need for collaboration across stakeholders, from biotechs and manufacturers to regulatory bodies and supply chain providers. 

We are honored to have our CEO featured in Pharma Focus Asia, contributing to the global discussion on CGT innovation. To gain deeper insights into Mark’s perspective on the future of the industry, read the full interview in the latest issue of Pharma Focus Asia.